Market Overview

Arena Pharmaceuticals Hires Kevin Lind As CFO

Share:

Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) revealed Wednesday that Kevin Lind would join its management team as EVP and CFO effective June 15, 2016. According to the company, Lind would report to Amit Munshi, its President and CEO.


Munshi commented, "Kevin is an accomplished executive with significant financial expertise and will be an exceptional addition to our team. Kevin's broad finance experience in the healthcare environment will be an asset to us as we move toward implementing a streamlined, flexible cost structure and operating model, while enabling us to focus on our highest-potential value-driving opportunities."

Area said Lind comes to the company with 15 years of experience in healthcare banking and private equity. Before that, Lind was at TPG, most recently as a Principal at TPG Special Situations Partners and initially at TPG-Axon's Pharma Partners group. Lind started his career in various capacities as a healthcare investment banker at Lehman Brothers, Inc.

Lind reacted, "It is a tremendous opportunity to join Arena at such an exciting time. I believe Arena's pipeline has great potential with its current Phase 2 programs and I look forward to joining Arena's executive team to assist in delivering significant value to patients and shareholders."

Posted-In: News Management

 

Related Articles (ARNA)

View Comments and Join the Discussion!
Fastest Market News Application
You'll Hear It First On Pro
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

H.C. Wainwright Downgrades United Therapeutics To Neutral

China Mobile Is Citi's Top Pick In China Telecom Space